C4A, or complement C4A (Rodgers blood group), was demonstrated to be downregulated in patients with diabetes who showed severe coronary artery stenosis and can serve as a plasma biomarker for predicting the severity of coronary artery atherosclerosis (29). This evidence concerns the gene C4A and diabetes mellitus.